Literature DB >> 7906726

Intrastriatal implantation of interleukin-1. Reduction of parkinsonism in rats by enhancing neuronal sprouting from residual dopaminergic neurons in the ventral tegmental area of the midbrain.

J Wang1, K S Bankiewicz, R J Plunkett, E H Oldfield.   

Abstract

Intrastriatal implantation with dopaminergic of nondopaminergic tissue can elicit behavioral recovery in parkinsonian animals. Because in these animals, especially in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned monkeys, there are still considerable numbers of dopaminergic neurons left in the mesencephalon, implantation-induced trophic effects on host residual dopaminergic neurons have been suggested as a mechanism underlying the behavioral recovery. Gliosis around the graft is a universal finding in any implantation procedure and is probably mediated by interleukin-1 (IL-1); in addition, activated astrocytes secrete several neurotrophic factors in vitro. Therefore, the authors postulated that trophic effects from IL-1-induced gliosis may be a "final common pathway" for recovery in parkinsonian animals after implantation. Hemiparkinsonism was induced in rats by injection of 6-hydroxydopamine either directly into the substantia nigra or into the median forebrain bundle. The substantia nigra-lesioned rats showed complete depletion of dopaminergic neurons in the substantia nigra but sparing of those in the ventral tegmental area, whereas the median forebrain bundle-lesioned animals had depletion of dopaminergic cells in the substantia nigra and the ventral tegmental area. Polymer pellets containing either slow-released IL-1 alpha and beta or placebo pellets were implanted in the caudate nucleus on the lesioned side in both groups. The rats' rotational response to amphetamine was tested weekly for 8 weeks. Selective substantia nigra-lesioned rats with implantation of IL-1 pellets had a 45% reduction in amphetamine-induced rotation, whereas placebo-implanted substantia nigra-lesioned rats had a 14% reduction in rotation. In the median forebrain bundle-lesioned group, neither IL-1 nor placebo implantation elicited any effect on turning. Immunohistochemical staining for glial fibrillary acidic protein was markedly increased surrounding the IL-1 pellets compared to the placebo pellets. In the selective substantia nigra-lesioned rats with IL-1 pellets implanted in the caudate nucleus, a considerable number of tyrosine hydroxylase immunoreactive (TH-IR) fibers were observed in the medial and middle portions of the caudate nucleus. Fewer TH-IR fibers were seen in the rats with placebo-bearing pellets. These results suggest that neurotrophic activities mediated by IL-1 and reactive astrocytes might be a common path through which tissue trauma and some tissue transplants exert their beneficial effects in parkinsonian animals. Furthermore, most of the sprouted dopaminergic fibers induced by IL-1 in the caudate nucleus come from dopaminergic neurons in the ventral tegmental area.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7906726     DOI: 10.3171/jns.1994.80.3.0484

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  18 in total

1.  Neurotrophic factors in neurodegenerative disorders: model of Parkinson's disease.

Authors:  J Garcia de Yebenes; J Yebenes; M A Mena
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

2.  Malfunctioning DNA damage response (DDR) leads to the degeneration of nigro-striatal pathway in mouse brain.

Authors:  Michal Kirshner; Ronit Galron; Dan Frenkel; Gil Mandelbaum; Yosef Shiloh; Zhao-Qi Wang; Ari Barzilai
Journal:  J Mol Neurosci       Date:  2011-09-16       Impact factor: 3.444

Review 3.  Perinatal Interactions between the Microbiome, Immunity, and Neurodevelopment.

Authors:  Geoffrey N Pronovost; Elaine Y Hsiao
Journal:  Immunity       Date:  2019-01-15       Impact factor: 31.745

4.  Characterization and transplantation of two neuronal cell lines with dopaminergic properties.

Authors:  F S Adams; F G La Rosa; S Kumar; J Edwards-Prasad; S Kentroti; A Vernadakis; C R Freed; K N Prasad
Journal:  Neurochem Res       Date:  1996-05       Impact factor: 3.996

5.  Interleukin-1β protects astrocytes against oxidant-induced injury via an NF-κB-dependent upregulation of glutathione synthesis.

Authors:  Yan He; Nicole A Jackman; Trista L Thorn; Valarie E Vought; Sandra J Hewett
Journal:  Glia       Date:  2015-04-16       Impact factor: 7.452

Review 6.  Neurotrophic factors for the investigation and treatment of movement disorders.

Authors:  Justo Garcia De Yébenes; Marina Sánchez; Maria Angeles Mena
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

7.  Interleukin-1 alpha polymorphism has influence on late-onset sporadic Parkinson's disease in Taiwan.

Authors:  Y R Wu; C M Chen; J C Hwang; S T Chen; I H Feng; H C Hsu; C N Liu; Y T Liu; Y Y Lai; H J Huang; G J Lee-Chen
Journal:  J Neural Transm (Vienna)       Date:  2007-04-26       Impact factor: 3.575

Review 8.  Therapeutic potential of nerve growth factors in Parkinson's disease.

Authors:  T J Collier; C E Sortwell
Journal:  Drugs Aging       Date:  1999-04       Impact factor: 3.923

9.  "Hydrocephalus-parkinsonism complex": progressive hydrocephalus as a factor affecting extrapyramidal tract disorder-an experimental study.

Authors:  Shizuo Oi; Dong Seok Kim; Mitsuru Hidaka
Journal:  Childs Nerv Syst       Date:  2003-11-05       Impact factor: 1.475

10.  Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase.

Authors:  M J During; J R Naegele; K L O'Malley; A I Geller
Journal:  Science       Date:  1994-11-25       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.